United Therapeutics Corporation UTHR

475.45 3.24 0.69% as of 25 Sep
Market cap
$20.3B
P/E
15.7×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
19.32% 20.26% 19.71% 20.04%

+8 more TTM periods

ROA
17.33% 17.81% 17.51% 17.57%
ROIC
23.44% 23.94% 22.34% 24.42%
Return on Tangible Assets
27.28% 31.30% 27.40% 28.24%
Average Days of Receivables
35.90 35.93 40.16 34.73
Free Cash Flow per Share
25.66 23.38 23.37 25.37
Free Cash Flow
1,093.00 1,016.90 1,035.20 1,111.20
Capital Expenditures
(592.20) (546.40) (526.00) (445.00)
Piotroski F-Score
4.00 6.00 7.00 7.00
Other line items
Cash ROIC
18.60% 19.41% 15.59% 16.63%
Accounts Receivable Turnover
9.15 10.00 10.11 9.78
Accounts Payable Turnover
0.94 0.98 0.92 0.86
Inventory Turnover
2.41 2.47 2.25 2.21
Average Days of Payables
415.59 427.65 463.37 478.62
Days of Inventory on Hand
161.80 153.02 173.86 180.51
Tax Rate
(0.17) (0.20) (0.22) (0.24)
Research and Development Expense of Revenue
17.48% 17.01% 17.28% 17.40%
Selling, General and Administrative Expense of Revenue
24.22% 24.29% 23.75% 23.45%
Share Based Compensation of Revenue
4.93% 4.73% 4.64% 4.34%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
1.29 1.21 1.17 1.22
Depreciation/Fixed assets
0.05 0.05 0.05 0.05
Capex/Depreciation
(6.47) (6.18) (6.14) (5.39)
Revenue per Share
74.05 72.87 71.84 71.42
Operating CF per Share
39.56 35.94 35.24 35.53
Capex per Share
(13.90) (12.56) (11.87) (10.16)
Capex to Sales
0.19 0.17 0.17 0.14
Net Profit Margin
41.56% 40.61% 41.94% 40.65%

Fold the line items

Columns are period end dates